Related Experiment Video

Updated: May 5, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.1K

Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy

Yoshiki Yamashita1, Katsuki Naitoh2, Hideo Wada3

  • 1Departments of Hematology and Oncology, Mie University Hospital and Mie University Graduate School of Medicine, Tsu, Japan.

Thrombosis Research
|December 12, 2013
PubMed
Abstract

Insights

Soluble platelet glycoprotein VI (sGPVI) levels are elevated in thrombotic microangiopathy (TMA) and disseminated intravascular coagulation (DIC). Measuring sGPVI aids in diagnosing and evaluating TMA, especially when ADAMTS13 levels are not markedly reduced.

Area of Science:

  • Hematology
  • Vascular Biology
  • Thrombosis Research

Background:

  • Thrombotic microangiopathy (TMA) encompasses diverse conditions.
  • Pathologies include reduced ADAMTS13 activity, endothelial cell injury, and platelet activation.
  • Platelet activation is a key factor in thrombotic states.

Purpose of the Study:

  • To investigate soluble platelet glycoprotein VI (sGPVI) levels in TMA patients.
  • To assess the role of sGPVI as a marker of platelet activation in thrombosis.

Main Methods:

  • Plasma levels of sGPVI were measured.
  • ADAMTS13 activity, von Willebrand factor (VWF), and VWF propeptide (VWFpp) were also quantified.
  • Patient cohorts included TMA, disseminated intravascular coagulation (DIC), and postoperative groups.

Main Results:

  • Significantly higher sGPVI levels were observed in TMA, DIC, and postoperative patients compared to non-thrombotic controls.
  • Elevated sGPVI was most pronounced in TMA patients with normal or near-normal ADAMTS13 activity.
  • Plasma exchange led to a significant reduction in sGPVI levels in TMA patients.

Conclusions:

  • sGPVI is a sensitive indicator of platelet activation in thrombotic conditions.
  • sGPVI measurement is valuable for diagnosing and monitoring TMA.
  • The marker is particularly useful in TMA cases not primarily driven by severe ADAMTS13 deficiency.
Keywords:
ADAMTS13Platelet activationTMAsGPVI

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K